A Phase II Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes

Trial Profile

A Phase II Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes

Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Nov 2017

At a glance

  • Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
  • Indications Haemangioendothelioma; Haemangiosarcoma; Leiomyosarcoma; Osteosarcoma; Sarcoma; Synovial sarcoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Aug 2016 Planned primary completion date changed from 1 Sep 2019 to 1 Aug 2019.
    • 16 Aug 2016 Status changed from not yet recruiting to recruiting.
    • 08 Jul 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top